Pharmacogenetic analysis of cinacalcet response in secondary hyperparathyroidism patients

BACKGROUND: Secondary hyperparathyroidism (SHPT) is one of the major risk factors of morbidity and mortality in end-stage renal disease. Cinacalcet effectively controls SHPT without causing hypercalcemia and hyperphosphatemia. However, there is significant inter-individual response variance to cinac...

Descripción completa

Detalles Bibliográficos
Autores principales: Jeong, Sohyun, Kim, In-Wha, Oh, Kook-Hwan, Han, Nayoung, Joo, Kwon Wook, Kim, Hyo Jin, Oh, Jung Mi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4944925/
https://www.ncbi.nlm.nih.gov/pubmed/27468225
http://dx.doi.org/10.2147/DDDT.S103370

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4944925/
https://www.ncbi.nlm.nih.gov/pubmed/27468225
http://dx.doi.org/10.2147/DDDT.S103370

Ejemplares similares